the lack of randomized controlled trials (RCTs) for direct comparison of Chinese patent medicine, and the inability of traditional meta-analyses to compare between different therapeutic effects, there is a lack of evidence as to which Chinese patent medicine is efficacious in the treatment of DN. Network meta-analysis (NMA) is an extension of traditional meta-analysis. Based on the frequency method or Bayesian theory, combined with direct and indirect comparison studies, the therapeutic effects of three or more interventions, can be compared. [4] The biggest advantage of NMA is that it can quantitatively compare different interventions in the treatment of the same disease and rank the efficacy of a certain outcome index, so as to provide evidence to support clinical drug selections. [5] Therefore, it is important to perform NMA to compare the efficacy between the Chinese patent medicine-ACEI/ARB combination group and ACEI/ARB alone.
MaterIals and Methods

Search strategy
This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses: The PRISMA Statement.
In this study, the following databases were searched: CNKI, Wanfang Data, VIP, PubMed, EMBASE, and the Cochrane Library. The search duration ranged from the inception of the individual database to August 2019. We also manually the reference lists of all full-text papers for additional relevant reports. The search terms used included "early DN," "diabetic renal disease," "Niaoduqing," "Jinshuibao," "Huangkui," "Bailing," "ACEI/ARB," and "randomized control."
Inclusion and exclusion criteria Study design
RCTs or quasi-RCTs were included, regardless of whether the blind methods were blinded, and the assignment was hidden or not. No restrictions on language, population characteristics, and publication types were imposed.
Participants
Patients with DN diagnostic standards were eligible for inclusion, and patients were classified as Stage I-III DN according to the Mogensen DN staging system. [6] 
Exclusion criteria
Exclusion criteria include (1) a control group was not included, or the control group was not designed to meet the principles of randomization or semi-randomization. (2) Animals experiments or cell experiments. (3) Theoretical articles and literature reviews. (4) Interventions included other traditional patent medicine. (5) Data were not available for analysis, or the article was identified as a repetitive publication. (6) Retrospective studies. (7) The target population did not meet the diagnostic criteria for DN Stages I-III diagnosis according to the Mogensen staging system.
Interventions
The study compared four different Chinese patent medicines-ACEI/ARB combinations with ACEI/ARB alone, regardless of the dosage, type, and duration of treatment. The basic therapies in the four kinds of Chinese patent medicines -ACEI/ARB combination group and ACEI/ARB group were similar.
Outcomes
The primary outcomes were the 24-h UTP, urinary microalbumin excretion (UAER), blood urea nitrogen (BUN), serum creatinine (Scr), and total effective rate. Secondary outcomes were glycosylated hemoglobin (HbAlc) level.
Efficacy criteria
Remarkable effect: Decrease in Scr decreased by 15%-30% or more; or increase in Ccr increased by »15% and obvious improvement in the clinical symptoms. Moderate effect: Decrease in Scr by 5%-15%; or increase in Ccr by 5%-15%, with partial improvement in clinical symptom. No effect: Therapy did not provide the standard of efficiency, and moreover, the clinical symptoms exacerbation. Therefore, total effect = remarkable effect + moderate effect.
Data extraction
Two investigators (Zhang J and Huang JQ) independently extracted information from the selected publications. The extracted contents included author (year), sample size, disease stage, patient age, interventions, comparators, treatment period, outcome measures, and main results. The difference of opinions was resolved by consultation with the corresponding author (Li J), who made an independent assessment and provided the final judgment.
Risk of bias assessment
Two investigators (Zhang J and Huang JQ) independently evaluated the quality of the selected publications using the Cochrane Collaboration's risk of bias tool. Assessments included random sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other possible biases. Using relevant criteria listed in The Cochrane Handbook for Systematic Reviews of Interventions, the publications were categorized as having "low risk of bias," "high risk of bias," and "unclear risk of bias."
Statistical analyses
Statistical analyses were performed using in The R Project for Statistical Computing (R version 3.5.1, Vienna, Austria, active worldwide), Generate Mixed Treatment Comparisons (Groningen, The Netherlands), and STATA 14.0 softwares(Texas, USA). Risk ratio and a 95% confidence interval were measured for dichotomous variables. Continuous data are presented as mean difference with 95% CI.
results
Studies identified
From among 2442 articles, 78 RCTs were finally included in the NMA. All the RCTs were conducted in China and published in Chinese. Figure 1 shows the search process and study selection.
Study characteristics
All 78 RCTs were published between 2007 and 2019. A total of 5984 participants were included (3010 in the Chinese patent medicine-ACEI/ARB combination group and 2974 in the ACEI/ARB group). The sample sizes of the included studies ranged from 40 to 205. All 78 studies included the corresponding basic treatments in the treatment strategy. The duration of the combination treatment ranged from 4 to 48 weeks. Characteristics of the included trials are listed in Table 1 .
Quality of the included studies
Randomized was mentioned in all 78 studies. However, only 24 trials claimed that they had used the random number table or random synthesis sequential. Only 2 trials mentioned single blind. In addition, all the trials did not mention allocation concealment. Therefore, the risk of bias of included studies was high. More details of the trials were presented in Figure 2 .
Outcome measures
Total effective rate All 78 RCTs included herein, all of which were dual-arm studies; therefore, a consistency test was not required. The effective evidence network of five therapeutic measures for early DN is shown in Figure 3 .
NMA of 21 trials was conducted to compare the total effective rate of four Chinese patent medicines in the treatment of early DN. The results showed that the total effective rate of the Jinshuibao capsule-ACEI/ARB combination group and Huangkui capsule-ACEI/ARB combination groups was higher than that of the others, as shown in Figure 4 .
Quantitation of 24-h urine protein
The 24-h UTP was reported in 28 studies. Only the Jinshuibao capsule-ACEI/ARB combination group demonstrated a reduced 24-h UTP level [ Figure 5 ]. 
Urine microalbumin excretion rate
Blood urea nitrogen
There were 30 studies that reported BUN values in their results. Only the Huangkui capsule-ACEI/ARB combination group reduced BUN values [ Figure 10 ].
Glycosylated hemoglobin
Twenty-two studies reported HbAlc values in their results. The results show that only the Jinshuibao capsule-ACEI/ARB combination group reduced HbAlc values [ Figure 11 ].
Adverse reactions
Twenty-six studies reported adverse reactions in their results. The results show that only the Bailing capsule-ACEI/ARB combination group reduced the incidence of adverse reactions, whether the other combinations could not [ Figure 12 ].
Publication bias of effective rate
We used a funnel plot to visualize the publication bias of the effective rate. The scatter plot was generated using the effect value as the abscissa and sample size as the ordinate. Without any publication bias, the inverted funnel plot is basically appears symmetrical. However, because of publication bias, the inverted funnel plot is incomplete and partially asymmetrical. At present, the funnel plot was partially asymmetrical, which suggested the possibility of publication bias [ Figure 13 ].
dIscussIon
Significance of network meta-analysis
DN belongs to consumption and thirst-associate illness in Chinese medicine and considered to be caused by kidney damage. The disease primarily affects the kidneys and often involves the liver, spleen, and other organs. Subsequently, the heart and lung are also affected, resulting in the Five Visceral Disease. Ancient physicians treated it as kidney deficiency, whereas modern physicians also focus on blood stasis.
Niaoduqing granule is composed of 16 traditional Chinese medicines, the synergistic effect of these components can improve renal function through multiple targets and pathways, and effectively slow the development of DN. [85] Several clinical studies have also reported that Niaoduqing granule improves renal function, and prevents glomerulosclerosis and renal interstitial fibrosis. In addition, it can also protect the endothelial function of patients with DN. [86] Cai HD reported that yellow sunflowers from Sichuan, a traditional Chinese herbal medicine, are widely used in the treatment of renal diseases in China, it reduces diuresis, reduces swelling and aids detoxification. It is found that the Huangkui capsule, extracted from Sichuan yellow sunflowers, confers nephroprotection by reducing the contents of urinary protein, Scr and BUN in nephrotic rats, however, the underlying mechanism needs further exploration. [87] Ma T found that there were four active ingredients of Huangkui capsule, which confers a protective effect on the kidneys. [88] The Jinshuibao capsule is composed of artificially fermented Cordyceps sinensis hyphae (cs-4 strain), which can strengthen the lungs and kidneys, fills essence, and invigorates the qi. [89] It can relieve cough, reduce blood lipid levels and inflammation, strengthen the heart and lungs, and prevent plaque to accumulation. Relevant studies have shown that Jinshuibao capsule can effectively improve the phenomenon of renal blood perfusion in patients, prevent the impairment of the physiological function of renal tubules from being impaired, and effectively inhibit the fibrosis of renal tubules. [90] Bailing capsule is a commonly marketed artificial preparation made from Cordyceps sinensis hyphae. The pharmacologically active ingredient is present in the artificial extract of Cordyceps mycelia and has become an excellent substitute for natural Cordyceps sinensis. Clinical studies and animal experiments show that Bailing capsule can tonify and benefit the lungs and kidneys and has the ideal clinical effect of renal function improvement in patient with DN. [91] These four kinds of common Chinese patent medicines demonstrate good curative effects in a patient with DN, and therefore, can be used as excellent supplements in routine treatment using western medicine. Therefore, the NMA of four different Chinese patent medicines combined with ACEI/ARB in the treatment of early DN was a pressing necessity. 
Summaries of results
Limitations
1. The literature included in this study was not of superior quality. All the 78 trials included in this study described the use of randomization. However, no study provided the randomization protocol, and only 2 trials used blinded methods. These might have caused measurement bias and may have an impact on the overall quality of the NMA 2. The risk of bias among the included studies was high and may affect the strength of the results. Most trials with positive findings had a small sample size. All the included RCTs were published in Chinese 3. The trials included in this study had different treatment courses (range 4-48 weeks), many of which were short, had small sample size, lacked multicenter collaboration, and had differences in the evaluation of clinical efficacy judgment, all of these factors may have affected the reliability of the study results. Studies that reported adverse reactions were few, which might have contributed to limited research evidence.
conclusIon
The results in this study suggested that the combined treatment with Jinshuibao and Huangkui capsules with ACEI/ARB had superior effects on the total effective rate than treatment with ACEI/ARB. Jinshuibao capsule can reduce the 24-h UTP, UAER, Scr, and HbAlc levels, whereas, the Huangkui capsule could reduce BUN levels better than other treatment groups. However, compared with the ACEI/ARB group, only Bailing capsule-ACEI/ARB combination group demonstrated reduced the incidence of adverse reactions. The others cannot reduce the occurrence of adverse reactions. Adverse reactions primarily included cough, diarrhea, and fatigue. None of the adverse reactions required intervention. This observation, however, may have been caused by insufficient sample sizes of the included studies. Therefore, a more rigorous randomized, double-blind, multicenter, with a sufficiently large cohort is needed in future to validate the efficacy of Chinese patent medicines in combination with ACEI/ARB in the treatment of early DN. The Chinese patent medicines may have a significantly superior role in the treatment of early DN. 
